These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35245876)

  • 1. Effect of sampling time on urinary electrolytes following oral furosemide administration in dogs with myxomatous mitral valve disease.
    Sabetti MC; Fidanzio F; Troìa R; Perissinotto L; Romito G; Mazzoldi C; Quintavalla C; Crosara S; Dondi F
    J Vet Cardiol; 2022 Jun; 41():57-69. PubMed ID: 35245876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of urinary neutrophil gelatinase-associated lipocalin to detect renal tubular damage in dogs with stable myxomatous mitral valve disease.
    Troia R; Sabetti MC; Crosara S; Quintavalla C; Romito G; Mazzoldi C; Fidanzio F; Cescatti M; Bertazzolo W; Giunti M; Dondi F
    J Vet Intern Med; 2022 Nov; 36(6):2053-2062. PubMed ID: 36196592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of a combination of pimobendan, furosemide, and enalapril on heart rate variability in naturally occurring, symptomatic, myxomatous mitral valve degeneration dogs.
    Pirintr P; Saengklub N; Boonpala P; Hamlin RL; Kijtawornrat A
    BMC Vet Res; 2023 Oct; 19(1):201. PubMed ID: 37821927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urine 5-hydroxyindoleacetic acid in Cavalier King Charles spaniels with preclinical myxomatous mitral valve disease.
    Christiansen LB; Cremer SE; Helander A; Madsen T; Reimann MJ; Møller JE; Höglund K; Ljungvall I; Häggström J; Olsen LH
    Vet J; 2019 Aug; 250():36-43. PubMed ID: 31383418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral blood lymphocyte subtypes in dogs with different stages of myxomatous mitral valve disease.
    Druzhaeva N; Nemec Svete A; Ihan A; Pohar K; Domanjko Petrič A
    J Vet Intern Med; 2021 Sep; 35(5):2112-2122. PubMed ID: 34236111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors affecting the urinary aldosterone-to-creatinine ratio in healthy dogs and dogs with naturally occurring myxomatous mitral valve disease.
    Galizzi A; Bagardi M; Stranieri A; Zanaboni AM; Malchiodi D; Borromeo V; Brambilla PG; Locatelli C
    BMC Vet Res; 2021 Jan; 17(1):15. PubMed ID: 33413406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutrophil-to-lymphocyte ratio is increased in dogs with acute congestive heart failure secondary to myxomatous mitral valve disease compared to both dogs with heart murmurs and healthy controls.
    DeProspero DJ; Hess RS; Silverstein DC
    J Am Vet Med Assoc; 2023 Nov; 261(11):1-8. PubMed ID: 37406992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of reoccurrence of congestive signs within 180 days after successful treatment of the first episode of congestive heart failure in dogs with myxomatous mitral valve disease.
    Franchini A; Abbott JA; Tyrrell W; Rosenthal S; Lahmers S; Menciotti G; Crosara S; Häggström J; Borgarelli M
    J Vet Cardiol; 2021 Apr; 34():112-119. PubMed ID: 33706221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aldosterone breakthrough in dogs with naturally occurring myxomatous mitral valve disease.
    Ames MK; Atkins CE; Eriksson A; Hess AM
    J Vet Cardiol; 2017 Jun; 19(3):218-227. PubMed ID: 28576479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiorenal and endocrine effects of synthetic canine BNP1-32 in dogs with compensated congestive heart failure caused by myxomatous mitral valve disease.
    Yata M; Kooistra HS; Beijerink NJ
    J Vet Intern Med; 2019 Mar; 33(2):462-470. PubMed ID: 30703246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure.
    Häggström J; Lord PF; Höglund K; Ljungvall I; Jöns O; Kvart C; Hansson K
    J Vet Intern Med; 2013; 27(6):1452-62. PubMed ID: 24128373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron parameters analysis in dogs with myxomatous mitral valve disease.
    Kumiega E; A Kobak K; Noszczyk-Nowak A; Kasztura M
    BMC Vet Res; 2024 May; 20(1):210. PubMed ID: 38762716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic value of atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP) and their correlation with lipoproteins in dogs with myxomatous mitral valve disease.
    Khaki Z; Nooshirvani P; Shirani D; Masoudifard M
    BMC Vet Res; 2022 Dec; 18(1):448. PubMed ID: 36564735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prevalence of pulmonary hypertension in Cavalier King Charles spaniels compared with other breeds with myxomatous mitral valve disease.
    Sudunagunta S; Green D; Christley R; Dukes-McEwan J
    J Vet Cardiol; 2019 Jun; 23():21-31. PubMed ID: 31174726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic assessment of diuretic efficacy and braking in a furosemide continuous infusion model.
    Adin D; Atkins C; Papich MG
    J Vet Cardiol; 2018 Apr; 20(2):92-101. PubMed ID: 29483040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the diagnostic value of the renal resistive index as a marker of the subclinical development of cardiorenal syndrome in MMVD dogs.
    Szczepankiewicz B; Pasławska U; Siwińska N; Plens K; Pasławski R
    J Renin Angiotensin Aldosterone Syst; 2021; 22(1):1470320321995082. PubMed ID: 33730896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of pimobendan on myocardial perfusion and pulmonary transit time in dogs with myxomatous mitral valve disease: a pilot study.
    Apple SM; Menciotti G; Braz-Ruivo L; Crosara S; Häggström J; Borgarelli M
    Aust Vet J; 2016 Sep; 94(9):324-8. PubMed ID: 27569835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The classical and alternative circulating renin-angiotensin system in normal dogs and dogs with stage B1 and B2 myxomatous mitral valve disease.
    Hammond HH; Ames MK; Domenig O; Scansen BA; Yang NT; Wilson MD; Sunshine E; Brunk K; Masters A
    J Vet Intern Med; 2023; 37(3):875-886. PubMed ID: 36951394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of endothelial cell-specific molecule-1 as a biomarker of glycocalyx damage in canine myxomatous mitral valve disease.
    Hong HJ; Oh YI; Park SM; An JH; Kim TH; Chae HK; Seo KW; Youn HY
    BMC Vet Res; 2022 Jul; 18(1):261. PubMed ID: 35790968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteomics reveals plasma protein SERPINH1 as a potential diagnostic biomarkers for myxomatous mitral valve disease stage B2.
    Zhou Q; Wu Z; Li L; Zhou H; Chen Y; Guo S; Guo Y; Ma X; Zhang J; Feng W; Cui X; Qiu C; Xu M; Deng G
    J Proteomics; 2023 Jun; 282():104924. PubMed ID: 37146676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.